Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure

Circulation

Volumn 106, Issue 23, 2002, Pages 2967-2972

  Suzuki, George ^a   Morita, Hideaki ^a   Mishima, Takayuki ^a   Sharov, Victor G ^a   Todor, Anastassia ^a   Tanhehco, Elaine J ^a   Rudolph, Amy E ^b   McMahon, Ellen G ^b   Goldstein, Sidney ^a   Sabbah, Hani N ^a,c  

^a Henry Ford Heart/Vascular Institute   (United States)

^b PFIZER INC   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

Heart failure; Hemodynamics; Remodeling

Indexed keywords

ALDOSTERONE ANTAGONIST; EPLERENONE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL EMBOLISM; CONTROLLED STUDY; DISEASE COURSE; DOG; DRUG EFFECT; FIBROSING ALVEOLITIS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE WALL; HEART MUSCLE CELL; HEART VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HEMODYNAMICS; HISTOPATHOLOGY; MEASUREMENT; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ALDOSTERONE ANTAGONISTS; ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOGS; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; FIBROBLAST GROWTH FACTOR 2; HEART; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; MYOCARDIUM; RNA, MESSENGER; SPIRONOLACTONE; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 0037016007     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000039104.56479.42     Document Type: Article

References (29)

1. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
2. Wilke A, Funck R, Rupp H, et al. Effect of the renin-angiotensin-aldo-sterone system on the cardiac interstitium in heart failure. Basic Res Cardiol. 1996;91(suppl 2):79-84.
3. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
4. Staessen J, Linjen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457-465.
5. de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spirolactone derivatives: Characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240:650-656.
6. Sabbah HN, Stein PD, Kono T, et al. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol. 1991;260:H1379-H1384.
7. Sabbah HN, Shimoyama H, Kono T, et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation. 1994;89:2852-2859.
8. Weiss JL, Frederiksen JW, Weisfeldt ML. Hemodynamic determinants of the time-course of fall in canine left ventricular pressure. J Clin Invest. 1976;58:751-760.
9. Sabbah HN, Kono T, Stein PD, et al. Left ventricular shape changes during the course of evolving heart failure. Am J Physiol. 1992;263: H266-H270.
10. Sahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
11. Grossman W. Pressure measurement. In: Grossman W, Baim DS, eds. Cardiac Catheterization, Angiography, and Intervention. Philadelphia, Pa: Lea & Febiger; 1991:123.
12. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotension-2 type-1 receptor antagonists in rats with heart failure. J Clin Invest. 1997;99:1926-1935.
13. Chadwick V, Thomas BS, Mytsi L, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998;97:1708-1715.
14. Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol. 2002;39:351-358.
15. Brilla CG, Pick R, Tan LB, et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355-1364.
16. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension. 1994;24:571-575.
17. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76:1259-1265.
18. Francis J, Weiss RM, Wei SG, et al. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol (Heart Circ Physiol). 2001;281: H2241-H2251.
19. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563-575.
20. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol (Heart Circ Physiol). 2001;281:H647-H654.
21. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res. 2000;46:214-224.
22. Montesano R, Vassalli JD, Baird A, et al. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA. 1986;83:7297-7301.
23. Gupta AR, Dejneka NS, D'Amato RJ, et al. Strain-dependent anterior segment neovascularization following intravitreal gene transfer of basic fibroblast growth factor (bFGF). J Gene Med. 2001;3:252-259.
24. Hayek A, Culler FL, Beattie GM, et al. An in vivo model for study of the angiogenic effects of basic fibroblast growth factor. Biochem Biophys Res Commun. 1987;147:876-880.
25. Tomanek RJ, Sandra A, Zheng W, et al. Vascular endothelial growth factor and basic fibroblast growth factor differentially modulate early postnatal coronary angiogenesis. Circ Res. 2001;88:1135-1141.
26. Borow KM, Lang RM, Neumann A, et al. Physiologic mechanisms governing hemodynamic responses to positive inotropic therapy in patients with dilated cardiomyopathy. Circulation. 1988:77:635-637.
27. Burton AC. The importance of the shape and size of the heart. Am Heart J. 1957;54:801-809.
28. Gould KL, Lipscomb K, Hamilton GW, et al. Relation of left ventricular shape, function and wall stress in man. Am J Cardiol. 1971;34:627-634.
29. Kono T, Sabbah HN, Rosman H, et al. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol. 1992;20:1594-1598.